Jim Simons Angion Biomedica Corp. Transaction History

Renaissance Technologies LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.48 - $1.02 $13,768 - $29,258	-28,685 Reduced 23.57%	93,015 $54,000
Q4 2022 Feb 13, 2023	SELL	$0.8 - $1.0 $69,821 - $87,277	-87,277 Reduced 41.76%	121,700 $99,000
Q3 2022 Nov 14, 2022	SELL	$0.94 - $1.23 $4,251 - $5,563	-4,523 Reduced 2.12%	208,977 $192,000
Q2 2022 Aug 12, 2022	SELL	$1.1 - $2.23 $11,220 - $22,746	-10,200 Reduced 4.56%	213,500 $243,000
Q1 2022 May 13, 2022	BUY	$1.72 - $2.96 $56,072 - $96,496	32,600 Added 17.06%	223,700 $474,000

Q4 2021 Feb 11, 2022	BUY	$2.35 - $9.95 $449,085 - $1.9 Million	191,100 New	191,100 $554,000

Ticker ANGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,113,300
Description
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primaril...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.